On Invalid Date, Cartesian Therapeutics (NASDAQ: RNAC) reported Q4 2023 earnings per share (EPS) of -$41.70, up 4,733.33% year over year. Total Cartesian Therapeutics earnings for the quarter were -$177.66 million. In the same quarter last year, Cartesian Therapeutics's earnings per share (EPS) was $0.90.
As of Q2 2024, Cartesian Therapeutics's earnings has grown year over year. Cartesian Therapeutics's earnings in the past year totalled -$219.71 million.
What is RNAC's earnings date?
Cartesian Therapeutics's earnings date is Invalid Date. Add RNAC to your watchlist to be reminded of RNAC's next earnings announcement.
What was RNAC's revenue last quarter?
On Invalid Date, Cartesian Therapeutics (NASDAQ: RNAC) reported Q4 2023 revenue of $8.27 million up 50.78% year over year. In the same quarter last year, Cartesian Therapeutics's revenue was $16.80 million.
What was RNAC's revenue growth in the past year?
As of Q2 2024, Cartesian Therapeutics's revenue has grown -76.53% year over year. This is 221.15 percentage points lower than the US Biotechnology industry revenue growth rate of 144.63%. Cartesian Therapeutics's revenue in the past year totalled $26.00 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.